@article{952031698a644d03921f461b63e7907e,
title = "Propranolol or atenolol for the management of infantile hemangioma: Implications for long-term health: Implications for long-term health",
keywords = "adrenergic beta-antagonists, blood pressure, capillary hemangioma, child, growth and development, infant, long-term adverse effects, vascular malformations, vascular tissue neoplasms",
author = "M.F. Raphael and Hermans, {Mireille M.} and Pasmans, {Suzanne G. M. A.} and {de Laat}, {Peter C. J.} and Slieker, {Martijn G.} and Mendels, {Elodie J.} and {de Graaf}, Marlies and Langeveld, {Hester R.} and Renske Schappin and Rietman, {Andr{\'e} B.} and Breugem, {Corstiaan C.} and Breur, {Johannes M. P. J.} and {de Wildt}, {Saskia N.}",
note = "Funding Information: Funding sources: This investigator-initiated study was carried out with an unrestricted grant provided by Pierre Fabre Dermatologie.",
year = "2023",
month = jun,
day = "1",
doi = "https://doi.org/10.1016/j.jdin.2023.02.001",
language = "English",
volume = "11",
pages = "137--139",
journal = "JAAD International",
issn = "2666-3287",
publisher = "Elsevier Inc.",
}